A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 100 shares of TRDA stock, worth $1,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 69,676 99.86%
Holding current value
$1,923
Previous $987,000 99.9%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.85 - $16.45 $720,160 - $999,715
60,773 Added 87.22%
130,449 $1.86 Million
Q1 2024

May 15, 2024

BUY
$11.58 - $17.0 $806,848 - $1.18 Million
69,676 New
69,676 $987,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $603M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.